Trinity Biotech PLC
TRIB Healthcare Medical Devices
Trinity Biotech PLC’s revenue for fiscal 2025 (year ended December 2025) was $43.8 million, down 28.9% from fiscal 2024. In the quarter to March 2026, revenue grew 43.3%, EPS grew 52.1%, free cash flow grew 75.2% and total debt rose 29.9%, each against the same quarter a year earlier. Dividend growth for five consecutive years.
Follow TRIB
Trinity Biotech PLC (TRIB) EV/Sales
As of 16 October 2026, Trinity Biotech PLC (TRIB) trades at a EV/Sales of 3.0×. Over the past ten years it has ranged from 0.5× (June 2016) to 26.2× (January 2015); the current reading is higher than 88% of that period. That is above the Medical Devices industry median of 2.2× and below the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 3.3× | 83.70% |
| FY2024 | 1.8× | 27.00% |
| FY2023 | 1.4× | (12.61%) |
| FY2022 | 1.6× | 44.20% |
| FY2021 | 1.1× | (25.40%) |
| FY2020 | 1.5× | 26.97% |
| FY2019 | 1.2× | 15.80% |
| FY2018 | 1.0× | (31.24%) |
| FY2017 | 1.5× | (15.39%) |
| FY2016 | 1.8× | (32.83%) |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Mar 2026 | 3.1× | (6.60%) |
| Dec 2025 | 3.3× | 19.12% |
| Sep 2025 | 2.8× | 11.94% |
| Jun 2025 | 2.5× | 18.59% |
| 41 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| NVNO enVVeno Medical Corporation compare | −63.5× |
| CODX Co-Diagnostics, Inc. compare | −1.2× |
| AMIX Autonomix Medical, Inc. compare | n/m |
| WOK WORK Medical Technology Group LTD compare | n/m |
| TBIO Telesis Bio Inc. compare | 0.1× |
| INBS Intelligent Bio Solutions Inc. compare | 0.2× |
| VVOS Vivos Therapeutics, Inc. compare | 0.4× |
| TRIB Trinity Biotech PLC | 3.0× |
| VNRX VolitionRX Limited compare | 4.0× |
| Medical Devices industry median | 2.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)